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2434smaller study of patients on similar triple therapy, an
increased bleeding risk was reported, raising partic-
ular concern for this combination in the medical
community (5). We strongly disagree with the
characterization of prasugrel on top of aspirin and
warfarin as nonrecommended only in patients
$75 years of age. According to prasugrel’s package
insert, concomitant use of medications that increase
the risk for bleeding is a risk factor for bleeding.
Therefore, a nonrecommended indication is more
appropriate for all patients taking prasugrel as part of
triple-antithrombotic therapy.*Dimitrios Alexopoulos, MD
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61:2060–6.REPLY: Frequency of Inappropriate and
Nonrecommended Prasugrel Prescription
Great VariationsWe appreciate the comments of Dr. Alexopoulos and
colleagues regarding our study on the frequency
and practice-level variation in inappropriate and
nonrecommended prasugrel prescribing from the
National Cardiovascular Data Registry PINNACLE
Registry (1).We did ﬁnd differences in provider and insurance
characteristics, with patients who were receiving
prasugrel inappropriately being less likely to have
seen physicians (89.5% vs. 93.8%; p < 0.001) and to
have private insurance (53.8% vs. 64.3%; p < 0.001)
compared with patients receiving prasugrel appro-
priately. The PINNACLE Registry uses standard deﬁ-
nitions for all practices, but data are self-reported.
Some practice-level variation could be explained by
reporting bias, but this could not be ascertained from
the registry. Furthermore, we did want to evaluate
the off-label use of prasugrel in patients without
histories of acute coronary syndromes or not under-
going percutaneous coronary intervention, but this
information could not be reliably extracted, as data
about myocardial infarction and percutaneous coro-
nary intervention were available for only 12 months
before a patient’s visit.
The prasugrel package insert (2) does mention
weight <60 kg as an additional risk factor for
bleeding but does not specify that it is not recom-
mended. The approved dose of prasugrel is 5 mg/day
in patients weighing #60 kg, compared with the
standard dose of 10 mg/day in those weighing
>60 kg. We agree that despite decreased platelet
reactivity, the dose of 5 mg/day in patients weighing
#60 kg has not been studied prospectively to
determine its effect on ischemic outcomes compared
with clopidogrel (3) and warrants caution. Of
24,112 patients in our study who were receiving
prasugrel and had weight data available, 911 (4.11%)
weighed <60 kg.
We found that 4,248 of our overall cohort of 27,533
patients (15.4%) were receiving “triple therapy” with
aspirin, warfarin, and prasugrel. Among them, 319
received prasugrel inappropriately (history of tran-
sient ischemic attack or stroke) and 677 for non-
recommended indications (age $ 75 years with no
history of diabetes or myocardial infarction) likely
increasing their bleeding risk. We would like to draw
attention to this and are not stating that triple ther-
apy is not recommended only in patients $75 years of
age. Furthermore, we welcome the suggestion of the
need for outcome studies in these patients, but the
PINNACLE Registry at the time of the publication of
this report did not collect data on ischemic and
bleeding outcomes.*Ravi S. Hira, MD
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Detect Necrotic
Core–Rich Plaque?I read with great interest the paper by Pu et al. (1)
in the Journal and congratulate the investigators on
an excellent study, which contributes greatly to
our current knowledge of intravascular ultrasound
(IVUS). It is generally accepted that grayscale IVUS is
limited to the detection of lipid-rich necrotic core
lesions, and there is no speciﬁc grayscale ultrasonic
signature associated with necrotic core. However, Pu
et al.’s (1) IVUS histological validation study of 2,294
human coronary autopsy specimens from victims of
cardiovascular death showed that echo attenuation,
in particular that with superﬁcial location, is a reliable
grayscale IVUS signature for high-risk plaque con-
taining a large necrotic core. This novel ﬁnding is
interesting and has clinical relevance because the
assessment of high-risk plaque using conventional
grayscale IVUS, because of its wide availability, has
broad interest for cardiologists. However, 2 items
warrant further clariﬁcation for readers to use this
novel echo-attenuated signature in ischemic event
risk stratiﬁcation.First, although “echo-attenuated plaque” was
identiﬁed by the absence of ultrasound signal behind
plaque that was either hypoechoic or isoechoic to
reference adventitia but without bright calcium in
their study (1), it had previously been identiﬁed by
ultrasound attenuation behind either hypoechoic
plaque or hypoechoic or mixed plaque (2). Therefore,
the deﬁnition of echo-attenuated plaque would
have to be standardized for clinical practice
implementation.
Second, ﬁndings on the location of lipid/necrotic
core in echo-attenuated plaque in this in vitro study
(1) appear inconsistent with those in an in vivo study
by the same research team using IVUS–virtual his-
tology in patients with acute coronary syndromes in
whom necrotic core appeared at the echogenic “cap”
of the plaque but not at the site of echo attenuation
(3). Because ﬁbrous cap thickness and necrotic core
location are critical to plaque vulnerability, it might
be of value if Pu et al. provided quantitative infor-
mation on ﬁbrous cap thickness of echo-attenuated
plaque and interpreted the disparity between their
in vitro and in vivo study results.
In addition, given that echo-attenuated plaque has
not been described in the existing IVUS guidelines
(4,5), I believe that the current qualitative plaque
classiﬁcation scheme by IVUS grayscale image char-
acteristics should be updated on the basis of the
novel ﬁndings by Pu et al. (1) on echo-attenuated
plaque.*Erling Falk, MD
*University of Copenhagen
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Denmark
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